A型肉毒毒素治疗特发性眼睑痉挛的研究进展  

Research Progress of Botulinum Toxin Type A in the Treatment of Benign Essential Blepharospasm

作　　者：姜静怡 李蒙 邓雪娟 李紫菀 

机构地区：[1]黑龙江中医药大学研究生院,黑龙江 哈尔滨

出　　处：《临床医学进展》2023年第3期3626-3630,共5页Advances in Clinical Medicine

摘　　要：良性特发性眼睑痉挛(Benign Essential Blepharospasm, BEB)是常见的局灶性颅肌肌张力障碍之一,其特征是不自主的、反复发作的眼轮匝肌和眼周其他肌肉阵挛性痉挛。因其病因病机尚无统一说法,目前无明确的治愈方法。A型肉毒杆菌毒素(Botulinum Toxin type A, BoNT-A)是治疗BEB的一线药物,在临床应用广泛。本篇对BEB的病因与发病机制,以及BoNT-A治疗BEB的作用机理与临床应用进展进行综述。Benign Essential Blepharospasm (BEB) is a common one of the focal cranial muscle dystonia, char-acterized by involuntary, repeated attacks of the orbicularis oculi muscle and other eye week myo-clonic seizures. Because of its etiology and pathogenesis has not been unified, there is no clear cure. Botulinum Toxin type A (BoNT-A) is a first-line drug in the treatment of BEB and has been widely used in clinic. This paper reviews the etiology and pathogenesis of BEB, as well as the mechanism of action and clinical application of BoNT-A in treating BEB.

关 键 词：A型肉毒毒素 良性特发性眼睑痉挛 综述 

分 类 号：R74[医药卫生—神经病学与精神病学]